45 Ha-Melakha Street
Entrance 3, Second Floor
About Theranica Ltd.Theranica is a medical device company that has combined neuromodulation therapy with modern wireless technology to develop proprietary wearable solutions that address various medical conditions and disease states. The noninvasive and therapeutic 'smart' patches are controlled by a smartphone app to allow for personalized, portable, and affordable care. The patch consists of a proprietary 'smart' chip that delivers electrical pulses to neuro-modulate the sensory nerves under the skin. The first application of the technology is for treatment of migraine headaches.
Co-Founder and CEO: Alon Ironi
Co-Founder, CFO & COO: Hamutal Raab
Co-Founder and VP, Marketing & Sales: Ronen Jashek,
Co-Founder and VP, Research & Development: Rostislav (Slava) Barabash
Director, Clinical and Regulation: Lana Volokh, PhD.
Please click here for Theranica job opportunities.
Please click here for Theranica's technology.
23 articles about Theranica Ltd.
Theranica announced a strategic license and supply agreement with Dr. Reddy's Laboratories Ltd., a global pharmaceutical company, for the exclusive marketing and distribution of FDA-approved Nerivio® in India, subject to completion of the regulatory approval process in India.
Theranica announced today it has teamed up with Point32Health, the parent organization of Harvard Pilgrim Health Care and Tufts Health Plan, to conduct a 12-month pilot aimed at treating the organization's commercial members suffering from episodic and chronic migraine.
Theranica today announced the closing of its Series C funding round, with a first closing of $45 million.
MC-Rx Formalizes Pharmacy Benefit Coverage for Theranica's Nerivio®, Providing Millions of Covered Members Access to the Novel Drug-Free Migraine Therapeutic
Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, announced it has signed an agreement with pharmacy benefit manager MC-Rx, which places Theranica's flagship Nerivio® device for acute treatment of migraine under MC-Rx's Pharmacy Benefit formulary.
The First Smartphone-Controlled, Prescription Wearable Device for the Acute Treatment of Migraine, Nerivio, Wins Silver at MDEA
Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, announced that its Nerivio® therapeutic wearable has been selected as the winner of the "Best New Technology Solution for Pain Management" award in the fifth annual MedTech Breakthrough Awards program conducted by MedTech Breakthrough.
Theranica , a prescribed digital therapeutics (PDT) company developing advanced electroceuticals for migraine and other pain conditions, today announced that its Nerivio ® therapeutic device has has received the Food and Drug Administration clearance to market for an expanded indication for acute treatment of episodic or chronic migraine in people 12 years and older.
Theranica , a prescribed digital therapeutics (PDT) company developing advanced electroceuticals for migraine and other pain conditions, today announced the addition of Donald Jones to its board of directors.
New Peer-reviewed Article Publishes Results of Clinical Study Testing Safety and Efficacy of Remote Electrical Neuromodulation for Acute Treatment of Migraine in Patients Aged 12-17
Nerivio® Smartphone-Controlled Wearable for Acute Treatment of Migraine Granted CE Mark for Use in Europe
Theranica Announces Nerivio will be Available in Select European Countries Starting in 2021
Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today announced that a new peer-reviewed study demonstrates the utility of incorporating Remote Electrical Neuromodulation (REN) into usual care of chronic migraine.
Theranica Kicks Off Migraine Awareness Month Rebate Program for Nerivio®, Its FDA-Authorized Migraine Treatment Wearable
Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today announced its Migraine Awareness Month $50 rebate for new Nerivio® prescriptions dispensed during June 2020.
Theranica Expands Executive Team Amid Growing US Demand for Its FDA-authorized Migraine Treatment Wearable Device
Theranica today announced the appointment of two senior executives amid growing demand for the company's prescription migraine treatment device Nerivio®.
Developer of Nerivio™, a Drug-Free Therapeutic Wearable for the Acute Treatment of Migraine,
BioMed Tech Developer Included in "Electro-Charged Therapeutics" Category Recognizing Companies Creating a Drug-Free Future
Theranica Announces U.S. Recycling Partnership in Commitment to Sustainable Medical Device Production
Partnership Advances Circular Economy by Making Nerivio™, a Prescribed Wearable for Acute Treatment of Migraine, Recyclable
Theranica: New Publication Compares Remote Electrical Neuromodulation for Acute Treatment of Migraine to Treatment with Acute Medications
Theranica, a bio-medical technology company developing advanced electroceuticals for migraine and other pain disorders, announced today the publication of a peer-reviewed paper demonstrating that Remote Electrical Neuromodulation (REN) is as effective as acute pharmacological treatments in treating the symptoms of migraine.
FDA Grants Theranica De Novo to Market First Smartphone-controlled Acute Migraine-relief Wearable Device
Clinical Data Show 66.7% Pain Relief Response Within Two Hours
Strategic investment signals positive response of healthcare community to Theranica's new approach to migraine management
aMoon leads round B of financing of the Israel-based company